Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Marinomed Biotech AG, corporate

Marinomed Biotech AG,

26.05.2021 - 07:48:06

Marinomed Biotech AG Reports Financial Results for 1st Quarter 2021: Growth in Sales, due to persistent strong demand in Carragelose-based virus blockers

All amounts in ? thousand Q1 2021 Q1 2020 Revenues 2,217.2 1,013.9 Personnel expenses 1,171.9 1,013.6 R&D expenses 2,170.0 863.5 Operating result (EBIT) -1,741.9 -1,406.5 Total comprehensive loss for the period -2,095.8 -1,574.9 Cash flow utilized in operating activities -3,721.3 -1,588.2 Total change in cash & cash equivalents -4,063.9 -1,790.3 ? ???? as of 31.03.2021 ???? as of 31.12.2020 Capital and reserves 3,454.6 5,357.6 Cash and cash equivalents 5,143.0 9,206.9 ?

The full quarterly statement can be found on the Company's website: https://www.marinomed.com/en/investors/publications ?

Conference Call Details:

Marinomed Biotech AG (VSE:MARI) will talk about these first quarter financial results in an international conference call (held in English language), today. The conference call is scheduled for 10.00 a.m. CET (9.00 a.m. GMT). Your conference call partners will be Dr. Andreas Grassauer, CEO, and Pascal Schmidt, CFO.

Participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call:https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=4875402&linkSecurityString=7deb4cd52

The presentation can be downloaded approx. 15 minutes before the conference call from the Company's website: https://www.marinomed.com/en/investors/publications

About Marinomed Biotech AG Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com/en/technologies-markets/markets.

For further inquiries contact:

Marinomed Biotech AG Pascal Schmidt, CFO Hovengasse 25, 2100 Korneuburg, Austria???????? T +43 2262 90300 E-mail: ir@marinomed.comhttp://www.marinomed.com International Media and IR Contact MC Services AG Dr. Brigitte Keller, Julia Hofmann T +49 89 210228 0UK: Shaun Brown M: +44 7867 515 918 E-mail: marinomed@mc-services.eu ?

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.

26.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1200489??26.05.2021?

@ dgap.de